Ellen C Minnihan - JoVE Visualize

Showing results (11-20 of 19) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 19 results.

Inorganic Chemistry|October 11, 2005

Phosphate triester hydrolysis promoted by an N2S(thiolate)Zn complex: mechanistic implications for the metal-dependent reactivity of peptide deformylaseDavid P Goldberg, Robert C diTargiani, Frances Namuswe, et al.

Biochemistry|January 20, 2017

Glutamate 350 Plays an Essential Role in Conformational Gating of Long-Range Radical Transport in Escherichia coli Class Ia Ribonucleotide ReductaseKanchana Ravichandran, Ellen C Minnihan, Qinghui Lin, et al.

The AAPS Journal|November 16, 2014

Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primerAnnette Bak, Dennis Leung, Stephanie E Barrett, et al.

Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013

Generation of a stable, aminotyrosyl radical-induced α2β2 complex of Escherichia coli class Ia ribonucleotide reductaseEllen C Minnihan, Nozomi Ando, Edward J Brignole, et al.

Molecular Cancer Therapeutics|November 24, 2021

STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic TumorsSamanthi A Perera, Johnny E Kopinja, Yanhong Ma, et al.

RSC Medicinal Chemistry|August 6, 2021

Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.

Science (New York, N.Y.)|August 22, 2020

An orally available non-nucleotide STING agonist with antitumor activityBo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, et al.

ACS Medicinal Chemistry Letters|July 14, 2026

Discovery of MK-2118, a Small-Molecule Agonist of STINGTimothy Henderson, Michael D Altman, Alexei V Buevich, et al.

Journal of Medicinal Chemistry|December 8, 2022

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.

Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 19 results.

Inorganic Chemistry|October 11, 2005

Phosphate triester hydrolysis promoted by an N2S(thiolate)Zn complex: mechanistic implications for the metal-dependent reactivity of peptide deformylaseDavid P Goldberg, Robert C diTargiani, Frances Namuswe, et al.

Biochemistry|January 20, 2017

Glutamate 350 Plays an Essential Role in Conformational Gating of Long-Range Radical Transport in Escherichia coli Class Ia Ribonucleotide ReductaseKanchana Ravichandran, Ellen C Minnihan, Qinghui Lin, et al.

The AAPS Journal|November 16, 2014

Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primerAnnette Bak, Dennis Leung, Stephanie E Barrett, et al.

Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013

Generation of a stable, aminotyrosyl radical-induced α2β2 complex of Escherichia coli class Ia ribonucleotide reductaseEllen C Minnihan, Nozomi Ando, Edward J Brignole, et al.

Molecular Cancer Therapeutics|November 24, 2021

STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic TumorsSamanthi A Perera, Johnny E Kopinja, Yanhong Ma, et al.

RSC Medicinal Chemistry|August 6, 2021

Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.

Science (New York, N.Y.)|August 22, 2020

An orally available non-nucleotide STING agonist with antitumor activityBo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, et al.

ACS Medicinal Chemistry Letters|July 14, 2026

Discovery of MK-2118, a Small-Molecule Agonist of STINGTimothy Henderson, Michael D Altman, Alexei V Buevich, et al.

Journal of Medicinal Chemistry|December 8, 2022

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.

Pageof 2